ImMucin (VXL100)
/ Vaxil Bio, BioVaxys
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 13, 2020
Vaxil Initiates Pre-Clinical Study in New Oncology Target
(GlobeNewswire)
- “VAXIL BIO LTD…is pleased to announce the initiation of the pre-clinical program for ImMucin™ in combination with the E-selectin binding polymer-based therapeutic (‘P-Esbp’), which Vaxil licensed for development and commercialization from BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev, Israel (‘BGU’).”
Preclinical • Oncology
1 to 1
Of
1
Go to page
1